CSIMarket Company Name, Ticker, Customers, else..
 
Jaguar Health Inc   (NASDAQ: JAGX)
 

Jaguar Health Inc's Suppliers Performance

JAGX's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
JAGX Costs vs Sales of Suppliers Growth Jaguar Health Inc recorded an increase in cost of sales by 95.64 % year on year, relative to one quarter ago cost of sales fell by -10.97 % in Q2.

• More on JAGX Suppliers



Jaguar Health Inc recorded increase in cost of sales by 95.64 % year on year, compare to one quarter ago cost of sales fell by -10.97 % in Q2.

• More on JAGX Suppliers




Jaguar Health Inc's Comment on Supply Chain


Napo sources CPL from suppliers and ships it to its third-party contract manufacturer, Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) in India, where CPL is processed into crofelemer at an FDA-approved facility. Napo is also establishing a second processing site operated by Indena S.p.A., a contract manufacturer based in Milan, Italy. Indena has completed validation activities and received approval from the Italian Medicines Agency (AIFA) to manufacture crofelemer drug substance. This enables Indena to supply crofelemer API for further development by Jaguar, supporting increased manufacturing demand pending potential FDA approval for new indications, including CTD.

Jaguar Health Inc's Comment on Supply Chain


Napo sources CPL from suppliers and ships it to its third-party contract manufacturer, Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) in India, where CPL is processed into crofelemer at an FDA-approved facility. Napo is also establishing a second processing site operated by Indena S.p.A., a contract manufacturer based in Milan, Italy. Indena has completed validation activities and received approval from the Italian Medicines Agency (AIFA) to manufacture crofelemer drug substance. This enables Indena to supply crofelemer API for further development by Jaguar, supporting increased manufacturing demand pending potential FDA approval for new indications, including CTD.







JAGX's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Jaguar Health Inc 0.42 27.81 -36.92 47
SUBTOTAL 0.00 0.00 0.00 -


Sources: Jaguar Health Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Jaguar Health Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.